Although GLP-1RAs can reduce body weight by 15%25% in controlled settings, real-world adherence is limited, and nearly 70% of patients experience weight regain after discontinuation, raising the risk of long-term pharmacological dependence ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications
GLP-1 receptors are found in non-neoplastic pancreatic islet cells, duodenal glands, stomach, breast tissue, lung and kidney vasculature, and brain tissue
This helps your provider determine whether GLP-1 therapy may be appropriate based on your individual goals and medical profile
The relationship between GLP-1 and brand-name medications is also worth understanding to navigate these discussions effectively
Damaged hepatocytes release ROS into the extracellular environment, thereby activating ROS-generating hepatic stellate cells